<DOC>
	<DOCNO>NCT01949324</DOCNO>
	<brief_summary>This study phase 2 , randomize , multi-center , single-masked study evaluate efficacy safety NT-501 implant participant Mactel .</brief_summary>
	<brief_title>A Phase 2 Multicenter Randomized Clinical Trial CNTF MacTel</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<criteria>Participant must offer sufficient opportunity review understand inform consent form , agree form 's content sign protocol 's informed consent Participant must least one study eye positive diagnosis MacTel Type 2 Participant must IS/OS PR break study eye ( ) en face ellipsoid zone ( area IS/OS loss ) measure SDOCT 0.16 mm2 4.00 mm2 If female , participant must incapable pregnancy If male , participant must agree use effective form birth control study Participant unable provide inform consent Participant le 21 year age great 80 year age Participant medically unable comply study procedure followup visit Participant study subject clinical trial intervention ( drug device ) within last 6 month Participant pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MacTel</keyword>
</DOC>